NASDAQ:ZLAB - Nasdaq - US98887Q1040 - ADR - Currency: USD
Taking everything into account, ZLAB scores 4 out of 10 in our fundamental rating. ZLAB was compared to 558 industry peers in the Biotechnology industry. While ZLAB seems to be doing ok healthwise, there are quite some concerns on its profitability. ZLAB is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -21.48% | ||
ROE | -31.09% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 63.62% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Altman-Z | 4.06 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.26 | ||
Quick Ratio | 3.09 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 114.34 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:ZLAB (6/26/2025, 11:51:54 AM)
36.135
-0.83 (-2.23%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 114.34 | ||
P/S | 9.47 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.89 | ||
P/tB | 5.27 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -21.48% | ||
ROE | -31.09% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 63.62% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 425.79% | ||
Cap/Sales | 12.52% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.26 | ||
Quick Ratio | 3.09 | ||
Altman-Z | 4.06 |